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Abst rac t
Background and purpose: Multiple sclerosis (MS) is a chro-
nic inflammatory autoimmune disease of the central nervous
system. Genetic and environmental factors could not 
completely explain the pathogenesis of the disease. Among
environmental factors, infectious agents are of more interest
than other candidates, so Chlamydia pneumoniae (C. pneumo-
niae) may have a role in MS development or progression.
This study aimed to evaluate C. pneumoniae seropositivity in
MS patients.
Material and methods: Serum samples obtained from a cohort
of 85 patients with MS and from 50 age- and sex-matched 
controls were assessed for the presence of antibodies. IgM 
and IgG concentration for C. pneumoniae were determined with 
enzyme-linked immunosorbent assay (ELISA).
Results: The mean age was 33.8 (9.96) years in the MS group
and 33.9 (10.7) years in controls. Female/male ratio was 3.5 : 1
in the MS group; 69 patients (81%) had relapsing-remitting
course (RRMS) and 16 patients (19%) had secondary pro-
gressive course (SPMS). The median concentration of C. pneu-
moniae IgM in the MS group was 0.5 RU/mL (0.25-1) ver-
sus 0.5 RU/mL (0.3-0.8) in the control group (p = 0.66);
likewise, the median concentration of C. pneumoniae IgG in 
MS patients was 57.3 RU/mL (17.05-95.1) compared with
56.15 RU/mL (6.85-102.5) in the control group (p = 0.85).
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St reszczenie
Wstêp i cel pracy: Stwardnienie rozsiane (SR) jest prze-
wlek³¹ zapaln¹ chorob¹ autoimmunologiczn¹ oœrodkowe-
go uk³adu nerwowego. Czynniki genetyczne i œrodowisko-
we nie t³u macz¹ w pe³ni patogenezy choroby. Wœród
czynników œrodowiskowych szczególne zainteresowanie
budz¹ drob noustroje powoduj¹ce zaka¿enia. Chlamydia
pneumoniae (C. pneu moniae) mog³aby odgrywaæ rolê
w powstawaniu lub postêpie SR. Celem badania by³a oce-
na obecnoœci przeciwcia³ przeciwko C. pneumoniae w suro-
wicy chorych na SR.
Materia³ i metody: Od 85 chorych na SR i od 50 osób z gru-
py kontrolnej, dobranych pod wzglêdem wieku i p³ci, pobra-
no krew i za pomoc¹ testów immunoenzymatycznych 
(ELISA) zbadano stê¿enia IgM i IgG przeciwko C. pneu-
moniae w surowicy.
Wyniki: Œrednia wieku wynios³a 33,8 (9,96) roku w grupie
chorych na SR i 33,9 (10,7) roku w grupie kontrolnej.
W grupie chorych na SR proporcja kobiet do mê¿czyzn
wynios³a 3,5 : 1. U 69 pacjentów (81%) choroba mia³a 
przebieg nawracaj¹co-zwalniaj¹cy, a u 16 pacjentów (19%) –
wtórnie postêpuj¹cy. Mediana stê¿enia IgM przeciwko 
C. pneumoniae wynios³a 0,5 RU/ml (0,25–1) w grupie cho-
rych na SR w porównaniu z 0,5 RU/ml (0,3–0,8) w grupie
kontrolnej (p = 0,66). Mediana stê¿enia IgG przeciwko 
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Introduction
Multiple sclerosis (MS) is a chronic inflammatory
autoimmune disease of the central nervous system (CNS).
The pathological hallmark of MS is demyelinating plaques
accompanied by gliosis around the blood vessels [1].
The aetiology of MS is still unknown but it has been
postulated that both genetic and environmental factors
are involved in the pathogenesis of this debilitating dis-
ease. Among environmental factors, infectious agents
are of more interest than other candidates [2]. Over the
past years, many infectious agents such as EBV [3] and
HSV-6 [4] have been suggested as potential causes of
MS but inconsistent results have been obtained [5].
During recent years many studies have proposed a pos-
sible role for Chlamydia pneumoniae (C. pneumoniae) in
MS development [6]. Sriram found increased CSF
antibodies to C. pneumoniae in 86% of MS patients com-
pared with controls [6].
C. pneumoniae is an intracellular pathogen and
a member of the Chlamydia family. It is a common cause
of human respiratory disease and is transmitted from
human to human by the respiratory tract with an incu-
bation period of several weeks [7].
C. pneumoniae induces a persistent infection due to
the inability of the host to eradicate the pathogen, lead-
ing to a chronic infection. Several studies show that 
C. pneumoniae may alter the ability of microglial cells 
to enhance the cytokine production [8]. Therefore, 
C. pneumoniae could be considered as a potential factor
in the pathogenesis of many chronic CNS diseases such
as Alzheimer disease [9], atherosclerosis, stroke [10]
and MS [11].
The present study aimed to evaluate the seroposi-
tivity of C. pneumoniae in Iranian MS patients compared
to controls.
Material and methods
This study was conducted in Isfahan, the second
largest province of Iran, located in the central part of
Iran at the latitude 30-34°N and longitude 49-55°E,
with a population of more than 4 million.
People living in Isfahan are ethnically Persian,
belonging to Caucasian ethnicity. The total number of
patients suffering from MS in Isfahan was 1391 with
the prevalence of 35.5 per 100 000, according to a study
in the year 2006 [12]. The prevalence of MS in this
area is significantly greater than in many other Asian
countries [13].
Serum samples obtained from a cohort of 85 patients
with MS and from 50 age- and sex-matched controls
were assessed for the presence of antibodies. The con-
trol group was selected from healthy people. In both
groups, 7 mL of blood was taken and after centrifuga-
tion frozen at –70°C. Presence and concentration for 
C. pneumoniae IgM and IgG were determined by the
enzyme-linked immunosorbent assay (ELISA), using
C. pneu moniae IgG and IgM kit (Euroimmun, Ger-
many).
Our patients were randomly chosen from registered
patients of MS Clinics affiliated to the Isfahan Univer-
sity of Medical Sciences. Tenets of the current version
of the Helsinki Declaration were followed; institutio nal
ethical committee approval was granted, and the nature
of the trial was explained to the patients. After a detailed
discussion with the neurologist, each patient signed an
informed consent form.
The demographic data were analysed by Student’s
t-test. C. pneumoniae antibody levels (including IgM and
IgG) were compared in the two groups of MS patients
and controls by the Mann-Whitney U-test.
C. pneumoniae wynios³a 57,3 RU/ml (17,05–95,1) w grupie
chorych na SR w po równaniu z 56,15 RU/ml (6,85–102,5)
w grupie kontrolnej (p = 0,85). Mediana stê¿enia IgG prze-
ciwko C. pneumoniae wœród chorych na nawracaj¹co-zwal-
niaj¹ce SR wynios³a 55,1 RU/ml (20,7–88,6), a w grupie
chorych z postaci¹ wtórnie postêpuj¹c¹ choroby – 59,1
RU/ml (5,35–112) (p = 0,8). 
Wnioski: Wœród irañskich chorych na SR nie stwierdzono
zwi¹zku miêdzy SR a wystêpowaniem przeciwcia³ przeciw-
ko C. pneumoniae.
S³owa kluczowe: stwardnienie rozsiane, Chlamydia pneumo-
niae, ELISA.
Regarding the clinical course, C. pneumoniae IgG was 55.1
RU/mL (20.7-88.6) in RRMS and 59.1 RU/mL (5.35-112)
in SPMS (p = 0.8). 
Conclusion: No association was observed between MS and 
C. pneumoniae in Iranian MS patients.
Key words: multiple sclerosis, Chlamydia pneumoniae, 
ELISA.
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Results
Eighty-five MS patients (67 females and 18 males)
and 50 controls (38 females and 12 males) were includ-
ed (P > 0.05). Female/male ratio was 3.5 : 1 in MS
patients. The mean age was 33.8 (standard deviation,
SD 9.96) years in the MS group and 33.9 (SD 10.7)
years in controls. Sixty-nine patients (81%) had relaps-
ing-remitting course (RRMS) and 16 patients (19%)
had secondary progressive course (SPMS).
The most common presenting symptoms were (in
order of decreasing frequency): optic neuritis, sensory
symptoms and motor signs. 
In the MS group, the mean interval between the first
and second attack was 1.74 (SD 1.96) years, mean dis-
ease duration was 5.8 (SD 4.66) years, mean number of
attacks per year was 1.40 (SD 0.83), and mean score of
the Expanded Disability Status Scale (EDSS) was 2.5
(SD 1.80). A positive family history of MS was found
in 13 pa tients (15.2%). 
The median concentration of C. pneumoniae IgM in
the MS group was 0.5 RU/mL (SD 0.25-1) versus 0.5
RU/mL (SD 0.3-0.8) in the control group (p = 0.66).
Likewise, the median concentration of C. pneumoniae
IgG in MS patients was 57.3 RU/mL (SD 17.05-95.1)
versus 56.15 RU/mL (6.85-102.5) in the control group
(p = 0.8) (Table 1).
C. pneumoniae IgG was 55.1 RU/mL (SD 20.7-
88.6) in RRMS and 59.1 RU/mL (SD 5.35-112) in
SPMS (p = 0.8).
Taken together, we did not observe any correlation
between either C. pneumoniae IgG or IgM and EDSS,
number of attacks and disease duration.
Discussion
Our study did not reveal any difference for the anti-
body response to C. pneumoniae between MS patients
and controls.
Multiple sclerosis is an autoimmune disease which
is more common in women than men; in our patients
the female-to-male ratio was 3.5 : 1, similar to many 
other studies [14,15] but higher than neighbouring
countries such as Pakistan and Iraq [13-16].
According to the geographical distribution of MS,
Isfahan province is expected to have a low-risk preva-
lence due to the latitude of the area. However, the results
of an epidemiological study showed an unexpected inci-
dence, with the prevalence of 35.5/100 000 (medium
risk) [12]. Although insufficient epidemiological stud-
ies have been performed over the past years in this
province, it seems that the prevalence of MS has been
growing in recent years rapidly. Therefore, a thorough
evaluation of the environmental factors, in particular
infectious agents, is warranted.
Recent evidence supported the notion that infections
associated with MS are ubiquitous. Thus, it is plausible
that the long-term presence of C. pneumoniae in the in -
fected tissue is able to bring about chronic inflamma-
tion in the target organ [17]. The Chlamydia family in -
Patients with Controls p-value
multiple sclerosis (n = 50)
(n = 85)
Age, years; mean (SD) 33.8 (9.96) 33.9 (10.7)
Sex
Women, n (%) 67 (78.8%) 38 (76%)
Men, n (%) 18 (21.2%) 12 (24%)
Disease duration, years; mean (SD) 5.8 (4.66)
EDSS score, mean 2.5
C. pneumoniae IgM positive (> 1.1 RU/mL) 14 (16.5%) 7 (14%) 0.8
C. pneumoniae IgG positive (> 22 RU/mL)   61 (71.8%) 35 (70%) 0.82
C. pneumoniae IgM level, median (interquartile range) 0.5 (0.3-0.8) 0.5 (0.25-1) 0.66
C. pneumoniae IgG level, median (interquartile range) 56.15 (6.85-102.5) 57.3 (17.05-95.1) 0.85
Table 1. Characteristics of studied groups
SD – standard deviation; EDSS – Expanded Disability Status Scale
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cludes four species: C. trachomatis, C. pneumoniae, 
C. psit taci, and C. pecorum. C. trachomatis and C. pneu-
moniae are common in humans but with different routes
of transmission and clinical presentation [7]. C. pneumo-
niae has been reported to be associated with neurologi-
cal diseases such as ischaemic stroke in young adults
[18], Alzheimer disease and MS.
One study showed that the neuronal cell line may be
markedly sensitive to C. pneumoniae [19] and it may play
an important role in the aetiology of MS. However, the
results of other studies are inconsistent, neither con-
firming nor excluding a possible role for C. pneumoniae
in MS development and progression [20].
Another study investigating the serum and cere-
brospinal fluid of MS cases for C. pneumoniae showed
the production of C. pneumoniae oligoclonal band IgG
only in a minority of MS patients [21]. On the other
hand, Sriram isolated C. pneumoniae from the CSF of
86% of MS patients compared with 11% of controls
[6]. The present study did not detect any association
between C. pneumoniae antibodies and MS patients, even
when evaluated with respect to the diseases stage. In con-
 trast to our result, Parratt et al. found C. pneumoniae
infection more commonly in MS patients than in con-
trols, particularly early in the course of the disease [22].
Although some investigations have shown a probable
association of C. pneumoniae with MS, we could not con-
firm the existence of an association. Similarly, Munger
et al. did not find any evidence of an association, repli-
cating and verifying our results [20].
Conclusion
No association was observed between MS and 
C. pneumoniae IgG and IgM antibodies in Iranian MS
patients.
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